ANTIBE THERAPEUTICS INC - ATBPF STOCK NEWS

Antibe Therapeutics Inc. (OTCQX: ATBPF) has announced a $6.5 million cash transaction to sell its Citagenix Inc. subsidiary to HANSAmed Limited. The deal, which includes guaranteed payments of $3.5 million and potential milestone payments of $3 million, allows Antibe to focus exclusively on its drug development pipeline. The transaction strengthens Antibe's balance sheet while facilitating growth in anti-inflammatory therapies. The closing is expected within 180 days.

Antibe Therapeutics Inc. (OTCQX: ATBPF) announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 3, 2022, at 2:00 PM ET in Toronto. CEO Dan Legault and Chief Medical Officer Dr. Joseph Stauffer will present the company's advancements in safer therapies targeting inflammation. The conference features 66 leading companies and will be accessible via a webcast on Antibe's website for 90 days following the event. Antibe focuses on hydrogen sulfide-based treatments, including its lead drug otenaproxesul for post-operative pain and ATB-352 for specialized pain indications.

Antibe Therapeutics Inc. has initiated its acute pain clinical program for otenaproxesul and ended the quarter with a $59 million cash position. The company is advancing multiple programs, including a focus on inflammatory bowel disease, and has filed new patents potentially extending IP protection into the 2040s. For the quarter ended December 31, 2021, net loss was $4.8 million, an improvement from $6.5 million year-over-year. The company maintains a strong cash runway, estimated to last over two years.

Antibe Therapeutics Inc. (OTCQX: ATBPF) has announced its financial results for the fiscal quarter ending September 30, 2021. The company ended the quarter with approximately $60 million in cash. A significant highlight includes the launch of otenaproxesul’s acute pain clinical program, set to begin early next quarter, alongside collaborations with pain specialists. The company reported a net loss of $8.7 million for the quarter, a slight decrease from $8.9 million in the same period last year.

Antibe Therapeutics Inc. (OTCQX: ATBPF) has outlined plans for the development of otenaproxesul as a non-opioid analgesic targeting acute pain, leveraging existing clinical data for a quicker path to market. The acute pain clinical program is set to begin in early Q1 2022, focusing on post-operative pain, with a projected market opportunity of $13 billion. Key milestones include initiating PK/PD studies and a Phase II trial in Q4 2022, followed by requests for FDA meetings. Antibe aims to expand applications of otenaproxesul beyond post-operative pain.

Antibe Therapeutics (OTCQX: ATBPF) has launched an acute pain program for its lead drug, otenaproxesul, targeting the $13 billion post-operative pain market. The company has filed a patent application to extend otenaproxesul’s intellectual property into the 2040s. While exploring alternative dosing regimens for osteoarthritis, the company’s strong cash position of $60 million will fund its development programs through 2024. The review also identified liver transaminase elevations in some subjects, which may need further investigation.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dan Legault and CMO Dr. Joseph Stauffer will present on September 13, available for on-demand viewing from 7:00 am ET. The webcast will be accessible for 90 days via the company's website. Antibe focuses on developing safer therapies for inflammatory conditions, with its lead drug otenaproxesul targeting osteoarthritis pain and future aims at inflammatory bowel disease.

Antibe Therapeutics Inc. (OTCQX: ATBPF) announced successful resolutions during its annual shareholder meeting, with all proposed directors elected. The results include:

• Walt Macnee: 86.88% approval
• Roderick Flower: 86.15% approval
• Robert Hoffman: 87.49% approval
• Amal Khouri: 86.91% approval
• Dan Legault: 71.86% approval
• Jennifer McNealey: 77.66% approval
• John L. Wallace: 73.35% approval
• Yung Wu: 86.73% approval

Voting results are filed on SEDAR, reinforcing Antibe's commitment to advancing its hydrogen sulfide platform for safer therapeutics.

Antibe Therapeutics Inc. (OTCQX:ATBPF) reported its fiscal Q1 2022 results, revealing a revenue increase to $2.7 million from $1.1 million year-over-year. Despite this growth, the company faced a net loss of $6.3 million. Otenaproxesul's AME study was paused due to safety concerns, with ongoing data analysis planned for updates in October. The company maintains a cash balance of $66.8 million, ensuring over two years of funding. Significant progress includes IND clearance for human trials and ongoing collaborations to expand its drug pipeline targeting inflammatory bowel disease.